Inhibikase Therapeutics Inc (IKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Sales | 7 | 46 | 2 | 329 | 1,363 |
| Gross Profit | 7 | 46 | 2 | 329 | 1,363 |
| Operating Expenses | 4,647 | 4,687 | 5,043 | 4,800 | 3,991 |
| Operating Income | -4,640 | -4,641 | -5,042 | -4,471 | -2,628 |
| Interest Expense | 0 | 0 | 0 | 0 | 8 |
| Pre-tax Income | -4,640 | -4,641 | -5,042 | -4,471 | -2,636 |
| Net Income Continuous | -4,640 | -4,641 | -5,042 | -4,471 | -2,636 |
| Net Income | $-4,640 | $-4,641 | $-5,042 | $-4,471 | $-2,636 |
| EPS Basic Total Ops | -1.10 | -1.08 | -0.90 | -1.08 | -1.32 |
| EPS Basic Continuous Ops | -1.10 | -1.10 | -0.94 | -1.07 | -1.29 |
| EPS Diluted Total Ops | -1.10 | -1.08 | -0.90 | -1.08 | -1.32 |
| EPS Diluted Continuous Ops | -1.10 | -1.10 | -0.94 | -1.07 | -1.29 |
| EBITDA(a) | $-4,640 | $-4,641 | $-5,042 | $-4,471 | $-2,628 |